NVOS

Novo Integrated Sciences, Inc. [NVOS] Stock Forecast

Q: What is Novo Integrated Sciences, Inc. stock symbol ?

Novo Integrated Sciences, Inc. is a US stock, located in Bellevue of Wa and trading under the symbol NVOS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NVOS Stock Summary

Earnings have grown 7.11% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Does not have any significance market cap ($8.07M)

Profit margins (-1.44%) are lower than the previous year (-1.05%)

NVOS has less than 1 year of cash runway

Top 10 Correlated ETFs

NVOS

Top 10 Correlated Stocks

NVOS

In the News

NVOS Financial details

Company Rating

Neutral

Market Cap

8.07M

Income

-13.96M

Revenue

13.04M

Book val./share

1.41

Cash/share

0.1

Dividend

Dividend %

Employees

127

Optionable

Shortable

Yes

Earnings

24 May 2024

P/E

-3.24

Forward P/E

PEG

0.36

P/S

0.92

P/B

2.36

P/C

4.66

P/FCF

-5.02

Quick Ratio

0.24

Current Ratio

0.56

Debt / Equity

0.2

LT Debt / Equity

0.07

EPS (TTM)

-1.16

EPS next Y

EPS next Q

EPS this Y

-88.48%

EPS next Y

EPS next 5Y

EPS last 5Y

48.5%

Revenue last 5Y

5.94%

Revenue Q/Q

17.8%

EPS Q/Q

40%

SMA20

-8.93%

SMA50

-32%

SMA100

-67.92%

Inst Own

4.15%

Inst Trans

1.5%

ROA

-51%

ROE

-73%

ROC

-0.31%

Gross Margin

39%

Oper. Margin

-68%

Profit Margin

-144%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.43-5.38

52W High

52W Low

RSI

44.31

Rel Volume

0.85

Avg Volume

567.3K

Volume

484.23K

Perf Week

-12.17%

Perf Month

-26.75%

Perf Quarter

-84.19%

Perf Half Y

-83.28%

Beta

-0.613

Volatility

0.05%, 0.06%

Prev Close

-8.53%

Price

0.4664

Change

-17.92%

NVOS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-08-31

Metric	2019-08-31	2020-08-31	2021-08-31	2022-08-31	2023-08-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.34	3.41	3.76	4.03	1.24
Net income per share	-0.18	-2.13	-1.8	-11.28	-1.3
Operating cash flow per share	-0.38	-0.19	-0.41	-2.02	-0.22
Free cash flow per share	-0.43	-0.2	-0.52	-2.09	-0.23
Cash per share	0.96	0.9	3.35	0.75	0.04
Book value per share	11.77	12.86	17.71	7.66	2.44
Tangible book value per share	1.18	1	0.92	-1.59	0.07
Share holders equity per share	11.77	12.86	17.71	7.66	2.44
Interest debt per share	2.04	1.98	5.6	7.06	0.94
Market cap	9.54M	9.21M	45.09M	48.49M	14.23M
Enterprise value	11.67M	11.54M	50.5M	59.31M	18.29M
P/E ratio	-24.34	-1.87	-10.1	-1.48	-1.08
Price to sales ratio	1.01	1.17	4.85	4.13	1.13
POCF ratio	-11.6	-20.86	-44	-8.24	-6.34
PFCF ratio	-10.26	-20.3	-35.21	-7.98	-6.21
P/B Ratio	0.37	0.31	1.03	2.17	0.57
PTB ratio	0.37	0.31	1.03	2.17	0.57
EV to sales	1.24	1.47	5.43	5.05	1.45
Enterprise value over EBITDA	-53.93	-3.91	-20.34	-9.27	-3.25
EV to operating cash flow	-14.19	-26.13	-49.28	-10.08	-8.15
EV to free cash flow	-12.55	-25.43	-39.43	-9.76	-7.98
Earnings yield	-0.04	-0.53	-0.1	-0.68	-0.93
Free cash flow yield	-0.1	-0.05	-0.03	-0.13	-0.16
Debt to equity	0.16	0.15	0.31	0.58	0.18
Debt to assets	0.13	0.12	0.22	0.32	0.13
Net debt to EBITDA	-9.83	-0.79	-2.18	-1.69	-0.72
Current ratio	1.35	1.65	1.32	0.41	0.56
Interest coverage	-3.54	-27.21	-26.51	-3.31	-1.67
Income quality	2.04	0.09	0.23	0.18	0.17
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.43	0.93	0.87	1.22	1.07
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.71	0.77	0.67	0.65	0.67
Capex to operating cash flow	0.13	0.03	0.25	0.03	0.02
Capex to revenue	-0.01	0	-0.03	-0.02	0
Capex to depreciation	-1.11	-0.01	-0.15	-0.06	-0.02
Stock based compensation to revenue	0.01	0.3	0.02	0.04	0.03
Graham number	6.91	24.85	26.79	44.09	8.45
ROIC	-0.04	-0.11	-0.08	-0.66	-0.39
Return on tangible assets	-0.04	-0.6	-0.22	-2.31	-1.12
Graham Net	-1.53	-0.97	-3.22	-5.3	-0.88
Working capital	1.07M	1.69M	2.67M	-8.34M	-3.52M
Tangible asset value	2.56M	2.31M	2.29M	-4.62M	698.05K
Net current asset value	-2.63M	-1.52M	-7.02M	-13.09M	-6.68M
Invested capital	0.16	0.15	0.31	0.58	0.18
Average receivables	1.75M	1.9M	2.16M	1.65M	1.24M
Average payables	1.23M	1.01M	1.17M	1.63M	2.66M
Average inventory	0	0	169.69K	609.21K	993.01K
Days sales outstanding	68.36	94.5	89.53	31.64	42.59
Days payables outstanding	70.79	67.17	96.52	94.7	168.33
Days of inventory on hand	0	0	22.6	46.24	53.03
Receivables turnover	5.34	3.86	4.08	11.54	8.57
Payables turnover	5.16	5.43	3.78	3.85	2.17
Inventory turnover	0	0	16.15	7.89	6.88
ROE	-0.02	-0.17	-0.1	-1.47	-0.53
Capex per share	-0.05	-0.01	-0.1	-0.07	0

Quarterly Fundamentals Overview

Last date of statement is 2023-11-30 for Q1

Metric	2022-11-30	2023-02-28	2023-05-31	2023-08-31	2023-11-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.01	0.32	0.23	0.21	0.23
Net income per share	-1.16	-0.58	-0.1	-0.2	-0.28
Operating cash flow per share	-0.08	-0.11	-0.06	-0.01	-0.13
Free cash flow per share	-0.08	-0.11	-0.06	-0.02	-0.13
Cash per share	0.26	0.08	0.03	0.03	0.1
Book value per share	6.19	3.43	1.85	1.57	1.41
Tangible book value per share	-1.36	0.28	0.14	0.04	0
Share holders equity per share	6.19	3.43	1.85	1.57	1.41
Interest debt per share	3.58	0.91	0.33	0.31	0.35
Market cap	8.43M	10.08M	18.96M	22.06M	20.07M
Enterprise value	18.02M	13.8M	23.07M	26.12M	23.07M
P/E ratio	-0.54	-0.55	-3.16	-1.75	-1.07
Price to sales ratio	2.47	3.94	5.76	6.68	5.16
POCF ratio	-30.3	-11.47	-22.1	-96.44	-9.33
PFCF ratio	-30.3	-11.47	-21.62	-85.14	-9.33
P/B Ratio	0.4	0.37	0.71	0.89	0.85
PTB ratio	0.4	0.37	0.71	0.89	0.85
EV to sales	5.27	5.4	7.01	7.91	5.93
Enterprise value over EBITDA	-10.9	-11.21	-29.26	-13.75	-6.8
EV to operating cash flow	-64.75	-15.71	-26.9	-114.17	-10.72
EV to free cash flow	-64.75	-15.71	-26.32	-100.79	-10.72
Earnings yield	-0.47	-0.46	-0.08	-0.14	-0.23
Free cash flow yield	-0.03	-0.09	-0.05	-0.01	-0.11
Debt to equity	0.5	0.16	0.17	0.18	0.2
Debt to assets	0.28	0.12	0.13	0.13	0.12
Net debt to EBITDA	-5.8	-3.03	-5.22	-2.13	-0.88
Current ratio	0.35	0.66	0.64	0.56	0.62
Interest coverage	-1.35	-0.62	-8.64	-6.31	-2.72
Income quality	0.07	0.19	0.58	0.07	0.46
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.16	1.08	0.83	1.22	1.35
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.67	0.68	0.68	0.67	0.62
Capex to operating cash flow	0	0	0.02	0.13	0
Capex to revenue	0	0	-0.01	-0.01	0
Capex to depreciation	0	0	-0.03	-0.05	0
Stock based compensation to revenue	0.02	0.02	0.08	0	0
Graham number	12.72	6.71	2.08	2.67	2.98
ROIC	-0.09	-0.08	-0.05	-0.13	-0.12
Return on tangible assets	-0.32	-0.39	-0.13	-0.27	-0.33
Graham Net	-4.42	-0.98	-0.52	-0.57	-0.58
Working capital	-8.11M	-2.13M	-2.21M	-3.52M	-4.11M
Tangible asset value	-4.62M	2.22M	2.05M	698.05K	25.05K
Net current asset value	-12.61M	-5.48M	-5.46M	-6.68M	-7.15M
Invested capital	0.5	0.16	0.17	0.18	0.2
Average receivables	988.75K	941.82K	1.13M	1.4M	2.05M
Average payables	1.94M	2.06M	1.97M	2.7M	3.46M
Average inventory	944.57K	967.61K	932.02K	1.02M	1.19M
Days sales outstanding	25.27	32.51	36.29	39.97	60.97
Days payables outstanding	111.18	115.8	86.23	133.15	157.32
Days of inventory on hand	54.12	52.51	42.7	41.95	58.74
Receivables turnover	3.56	2.77	2.48	2.25	1.48
Payables turnover	0.81	0.78	1.04	0.68	0.57
Inventory turnover	1.66	1.71	2.11	2.15	1.53
ROE	-0.19	-0.17	-0.06	-0.13	-0.2
Capex per share	0	0	0	0	0

NVOS Frequently Asked Questions

What is Novo Integrated Sciences, Inc. stock symbol ?

Novo Integrated Sciences, Inc. is a US stock , located in Bellevue of Wa and trading under the symbol NVOS

What is Novo Integrated Sciences, Inc. stock quote today ?

Novo Integrated Sciences, Inc. stock price is $0.4664 today.

Is Novo Integrated Sciences, Inc. stock public?

Yes, Novo Integrated Sciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Company Profile

Volume Average 567.3K
Market Capitalization 8.07M
Employee 127
CEO Mr. Robert Mattacchione
Headquarters Bellevue,WA,US
IPO Date 2021-02-23
Website https://novointegrated.com

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.